Metagenomi, Inc. (MGX) Dividend History

Company News

• Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025

  Metagenomi presented data at the ASGCT Annual Meeting 2025, showcasing advancements in its gene editing technologies, including compact nucleases for extrahepatic gene editing and CAST for site-specific integration of large therapeutic genes.

  GlobeNewswire Inc.
• Metagenomi to Present at Upcoming Scientific Meetings

  Metagenomi, a precision genetic medicines company, announced upcoming scientific presentations and provided updates on its gene editing technology and pipeline. The company highlighted positive results from a nonhuman primate study for its hemophilia A treatment and advancements in its CRISPR-associated transposase (CAST) systems.

  GlobeNewswire Inc.
• Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

  Totus Medicines, a company developing small molecule medicines using DNA-encoded covalent library technology and AI/ML, has appointed Simon Harnest as its new Chief Financial Officer. This appointment comes as the company prepares to advance its lead covalent PI3Kα inhibitor, TOS-358, following positive Phase 1 results.

  GlobeNewswire Inc.

  Featured Companies: CBUS
• Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting

  Metagenomi presented updated preclinical data for its hemophilia A program, including durable Factor VIII activity levels in an ongoing nonhuman primate study and positive results for its lead development candidate MGX-001.

  GlobeNewswire Inc.
• היום הוא המועד לתביעה נגד MGX: רוזן, פירמת עורכי דין מהשורה הראשונה, מעודדת את משקיעי Metagenomi, Inc לקבל ייעוץ לפני התאריך החשוב היום 25 בנובמבר בתביעה ייצוגית בניירות ערך – MGX

  Rosen Law Firm is encouraging Metagenomi, Inc. (MGX) investors to seek legal advice before the important November 25, 2024 deadline for a securities class action lawsuit. The lawsuit alleges that Metagenomi misled investors about its business relationship with Moderna during its IPO.

  GlobeNewswire Inc.

  Featured Companies: MRNA